Claims
- 1. A compound selected from the group consisting of an optically active compound of the formula: ##STR17## the mirror image isomer thereof, the racemic mixture of the optical isomers and the pharmacologically acceptable acid addition salts thereof wherein R.sub.1 is hydrogen or a moiety of the formula: ##STR18## wherein R.sub.3 is alkyl(C.sub.1 -C.sub.3), R.sub.2 is 3,4-methylenedioxyphenyl or a moiety of the formula: ##STR19## wherein R.sub.4 is chloro, bromo, alkanoyl(C.sub.2 -C.sub.4), alkylamino (C.sub.1 -C.sub.3), dialkylamino(C.sub.1 -C.sub.3), hydroxymethyl, benzyl or benzoyl with the proviso that when R.sub.1 is hydrogen then R.sub.4 may not be halogen.
- 2. The racemate according to claim 1 wherein R.sub.1 is hydrogen and R.sub.2 is para-acetylphenyl; dl-4'-(3-azabicyclo[3.1.0]hex-1-yl)acetophenone hydrochloride.
- 3. The racemate according to claim 1 wherein R.sub.1 is hydrogen and R.sub.2 is 3,4-methylenedioxyphenyl; dl-1-(3,4-methylenedioxyphenyl)-3-azabicyclo[3.1.0]hexane hydrochloride.
- 4. The enantiomer according to claim 1 wherein R.sub.1 is .alpha. methyl-phenylcarbamoylmethyl and R.sub.2 is para-chlorophenyl;1-1-(p-chlorophenyl)-.alpha.-methyl-3-azabicyclo[3.1.0]-hexane-3-acetanilide hydrochloride.
- 5. The racemate according to claim 1 wherein R.sub.1 is hydrogen and R.sub.2 is para-benzoylphenyl; dl-'4-(3-azabicyclo[3.1.0]hex-1-yl)benzophenone hydrochloride.
- 6. The racemate according to claim 1 wherein R.sub.1 is hydrogen and R.sub.2 is para-propionylphenyl; dl-4'-(3-azabicyclo[3.1.0]hex-1-yl)-propiophenone hydrochloride.
- 7. The racemate according to claim 1 wherein R.sub.1 is hydrogen and R.sub.2 is para-benzylphenyl; dl-1-(.alpha.-phenyl-p-tolyl)-3-azabicyclo[3.1.0]hexane.
- 8. The racemate according to claim 1 wherein R.sub.1 is hydrogen and R.sub.2 is para-hydroxymethyl; dl-p-(3-azabicyclo[3.1.0]hex-1-yl)benzyl alcohol.
- 9. The racemate according to claim 1 wherein R.sub.1 is hydrogen and R.sub.2 is para-diethylamino; dl-1-(p-diethyl aminophenyl)-3-azabicyclo[3.1.0]hexane dihydrochloride.
- 10. A method of treating depression in a mammal which comprises administering to said mammal an anti-depressant effective amount of a compound of claim 1.
- 11. A method of treating depression in a mammal which comprises administering to said mammal an anti-depressant effective amount of a compound of the formula: ##STR20## wherein R.sub.1 is hydrogen or alkyl(C.sub.1 -C.sub.3), R.sub.2 is hydrogen, alkyl(C.sub.1 -C.sub.3), cyclopropylmethyl, allyl or a moiety of the formula:
- C.sub.n H.sub.2n --R.sub.4
- wherein n is 1 or 2 and R.sub.4 is phenyl, halophenyl, naphthyl, norbornenyl or adamantyl, R.sub.3 is 3,4-methylenedioxyphenyl, 3,4,5-trimethoxyphenyl or a moiety of the formula: ##STR21## wherein R.sub.5 is hydrogen, halogen, hydroxy, alkoxy(C.sub.1 -C.sub.3), alkyl(C.sub.1 -C.sub.3) or trifluoromethyl, and R.sub.6 is hydrogen, halogen, alkoxy(C.sub.1 -C.sub.3), alkyl(C.sub.1 -C.sub.6), acyl(C.sub.2 -C.sub.4), amino, alkylamino(C.sub.1 -C.sub.3), dialkylamino(C.sub.1 -C.sub.3), hydroxymethyl, trifluoromethyl, phenyl, benzyl or benzoyl; the optical isomers thereof, the racemic mixtures thereof, or the pharmacologically acceptable acid-addition salts thereof.
- 12. The method according to claim 11 wherein the compound is 1-(p-chlorophenyl)-3-azabicyclo[3.1.0]hexane hydrochloride.
- 13. The method according to claim 11 wherein the compound is 1-phenyl-3-azabicyclo[3.1.0]hexane.
- 14. The method according to claim 11 wherein the compound is (+)-1-phenyl-3-azabicyclo[3.1.0]hexane hydrochloride.
- 15. The method according to claim 11 wherein the compound is 1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane hydrochloride.
- 16. The method according to claim 11 wherein the compound is 1-(m-methoxyphenyl)-3-methylazabicyclo[3.1.0]hexane hydrochloride.
- 17. The method according to claim 11 wherein the compound is 1-(m-hydroxyphenyl)-3-methyl-3-azabicyclo[3.1.0]hexane hydrochloride.
- 18. The method according to claim 11 wherein the compound is 1-(p-tolyl)-3-azabicyclo[3.1.0]hexane hydrochloride.
- 19. The method according to claim 11 wherein the compound is (+)-1-(p-tolyl)-3-azabicyclo[3.1.0]hexane hydrochloride.
- 20. The method according to claim 11 wherein the compound is 3-methyl-1-(p-tolyl)-3-azabicyclo[3.1.0]hexane hydrochloride.
- 21. The method according to claim 11 wherein the compound is 1-(p-tolyl)-3-azabicyclo[3.1.0]hexane.
- 22. The method according to claim 11 wherein the compound is 1-(3,4-dichlorophenyl)-3-methyl-3-azabicyclo[3.1.0]hexane hydrochloride.
- 23. The method according to claim 11 wherein the compound is 3-ethyl-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane hydrochloride.
- 24. A composition of matter for the treatment of depression characterized in that said composition contains as an active ingredient an anti-depressant effective amount of a compound of claim 1 in association with a pharmaceutically acceptable carrier.
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation-in-part of copending application Ser. No. 279,366, filed July 1, 1981, now abandoned.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4131611 |
Fanshawe et al. |
Dec 1978 |
|
Non-Patent Literature Citations (1)
Entry |
Epstein et al., J. Med. Chem., 24:481 (1981). |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
279366 |
Jul 1981 |
|